N1-Benzyl-N2-(5-methyl-[1,1'-biphenyl]-2-yl)oxalamide, 97%, 5g

2-(hydroxymethyl)-1,4-dihydropyridin-4-one, 97%, 1g

(5E)-5-[4-(allyloxy)benzylidene]-2-mercapto-1,3-thiazol-4(5H)-one, 95.0%, 5g

Crizotinib, 95%, 100mg

3,3-Diethyl-4-oxoazetidin-2-yl propionate, 97%, 250mg

4-(1-Hydrazinylethyl)benzoic acid compound with benzenesulfonic acid (1:1), 98%, 250mg

3-((Tert-butoxycarbonyl)amino)-3-(thiophen-2-yl)propanoic acid, 95+%, 25g

1,1-cyclobutanedicarboxylic acid, min. 98%, 25 g, plastic packaging.

1-(4-Cyclopropylphenyl)ethanone, 95.0%, 10g

8-Bromo-6-(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine, 98%, 5g

7-Bromo-4-chloro-1H-pyrrolo[3,2-c]pyridine, 100mg

(3-Amino-5-chlorophenyl)methanol, 95.0%, 250mg

rel-(1r,4r)-4-((2-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexan-1-ol, 98%, 50mg